

## Article

# Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer

Ching-Wen Huang<sup>1,2</sup>, Yen-Cheng Chen<sup>1,3</sup>, Tzu-Chieh Yin<sup>1,4,5</sup>, Po-Jung Chen<sup>1</sup>, Tsung-Kun Chang<sup>1</sup>, Wei-Chih Su<sup>1</sup>, Cheng-Jen Ma<sup>1,4</sup>, Ching-Chun Li<sup>1</sup>, Hsiang-Lin Tsai<sup>1,2</sup> and Jaw-Yuan Wang<sup>1,2,3,6,7,8,9\*</sup>

<sup>1</sup> Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>2</sup> Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>3</sup> Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>4</sup> Division of General and Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>5</sup> Department of Surgery, Kaohsiung Municipal Tatung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>6</sup> Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>7</sup> Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>8</sup> Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan

<sup>9</sup> Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, Taipei, Taiwan

\* Correspondence: Tel: +886-7-3122805; Fax: +886-7-3114679; cy614112@ms14.hinet.net; jawyuanwang@gmail.com

**Abstract:** This study investigated the roles of low-molecular-weight fucoidan (LMWF) in enhancing the anti-cancer effects of fluoropyrimidine-based chemotherapy. HCT116 and Caco-2 cells were treated with LMWF and 5-FU. Cell viability, cell cycle, apoptosis, and migration were analyzed in both cell types. Potential mechanisms underlying how LMWF enhances the anti-cancer effects of fluoropyrimidine-based chemotherapy were also explored. The cell viability of HCT116 and Caco-2 cells was significantly reduced after treatment with a LMWF-5-FU combination. In HCT116 cells, LMWF enhanced the suppressive effects of 5-FU on cell viability through the 1) induction of cell cycle arrest in the S phase and 2) late apoptosis mediated by the Jun-N-terminal kinase (JNK) signaling pathway. In Caco-2 cells, LMWF enhanced the suppressive effects of 5-FU on cell viability through both c-mesenchymal-epithelial transition (MET)/ Kirsten Rat Sarcoma virus (KRAS)/ extracellular signal-regulated kinase (ERK) and c-MET/ phosphatidylinositol 3-kinases (PI3K)/ protein kinase B (AKT) signaling pathways. Moreover, LMWF enhanced the suppressive effects of 5-FU on tumor cell migration through the c-MET/ matrix metalloproteinase (MMP)-2 signaling pathway in both HCT116 and Caco-2 cells. Our results demonstrated that LMWF is a potential complementary therapy for enhancing the efficacies of fluoropyrimidine-based chemotherapy in colorectal cancers (CRCs) with the wild-type or mutated *KRAS* gene through different mechanisms. However, *in vivo* studies and in clinical trials are required to validate the results of the present study.

**Keywords:** low-molecular-weight fucoidan; colorectal cancer; HCT116 cell; Caco-2 cell; fluoropyrimidine-based chemotherapy; complementary therapy

## 1. Introduction

Colorectal cancer (CRC) is reported to be the third most common type of malignancy and the third leading cause of cancer-related death worldwide [1]. In 2017, approximately 1.8 million new diagnoses of CRC and 896,000 CRC-related deaths were estimated globally [2]. In Taiwan, CRC has been the most common type of malignancy and the third leading cause of cancer-related death since 1996. In 2000 and 2017, the incidence was 32.38

and 66.32 per 100,000, respectively (with 7,213 and 16,408 new diagnoses, respectively). Moreover, 6,436 people died of CRC in 2019. The mortality rates were 27.3 and 20.6 per 100,000 in 2019 and 2009, respectively [3].


Fucoidan is an algal fucose-enriched sulfated polysaccharide molecule which is extracted from the extracellular matrix (ECM) of various types of brown seaweeds [4]. The main backbone of fucoidan is composed of (1→3)-linked  $\alpha$ -L-fucopyranosyl residues or of alternating (1→3)- and (1→4)  $\alpha$ -L-linked -l-fucopyranosyl residues [5,6]. Fucoidan also contains various quantities of other monosaccharides such as D-galactose, D-xylose, D-mannose, and uronic acid [5,6]. Fucoidan exhibits many biological activities, including anti-coagulant, antioxidant, anti-inflammatory, anti-proliferative, anti-diabetic, and anti-cancer activities [5–11]. The biological activities of fucoidan are reported to be associated with its structure and molecular weight [10,12]. Low-molecular-weight fucoidan (LMWF) has been reported to exhibit greater biological activity relative to high-molecular-weight fucoidan (HMWF) [5,10,12]. Hyperglycemia has been reported to be associated with risk and prognosis of CRC [13]. The anti-cancer activities of fucoidan have been revealed for various types of cancers, including hepatocellular carcinoma, lung cancer, breast cancer, CRC, pancreatic cancer, prostate cancer, and melanoma cancer [5–10].

Fluorouracil (5-FU) has been used as one of the main therapeutic agents for CRC since the 1990s [14]. Fucoidan exerts the anti-cancer activity, and LMWF is more biologically active. In our previous prospective, randomized, double-blind, controlled trial [15], 60 patients with metastatic CRC (mCRC) were enrolled and divided into two groups, namely a study group (n = 30) and control group (n = 30), and the aim was to evaluate the effects of LMWF when used as a supplement to chemotarget agents. Combination therapy of the FOLFIRI regimen (5-FU, folinic acid, and irinotecan) and bevacizumab (5 mg/kg) was administered biweekly as the first-line therapeutic regimen in all patients. Moreover, 4 g of LMWF (extracted from *Sargassum hemiphyllum*) was administered to patients in the study group. The disease control rate was significantly higher in the study group (92.8% vs 69.2%,  $p = 0.026$ ). Therefore, the benefit of supplemental therapy with LMWF was demonstrated; this therapy improved the disease control rate of patients with CRC [15]. Considering the results of our previous study [15], we hypothesized that LMWF enhances the anti-cancer effects of fluoropyrimidine-based chemotherapy. Patients with stage III CRC and positive expression of epidermal growth factor receptor (EGFR) have worse prognoses [16] and may require additional agents to enhance the efficacy of fluoropyrimidine-based chemotherapy. Therefore, we performed an *in vitro* study to investigate the roles of LMWF in enhancing the anti-cancer effect of fluoropyrimidine-based chemotherapy. Moreover, we attempted to identify the possible mechanisms underlying how LMWF enhances the anti-cancer effect of fluoropyrimidine-based chemotherapy.

## 2. Results

### 2.1. Effect of LMWF and 5-FU on cell viability

We observed a significantly lower viability of HCT116 and Caco2 cells at 24 h (all  $p < 0.05$ ; Figure 1A and 1B, respectively) after treatment with LMWF or 5-FU compared with control cells. Moreover, HCT-116 and Caco2 cells exhibited significantly much lower cell viability at 24 h (all  $p < 0.05$ ; Figure 1A and 1B, respectively) after treatment with the combination of LMWF and 5-FU compared with control cells, cells treated with LMWF, and those treated with 5-FU.



**Figure 1.** Effects of LMWF and 5-fluorouracil (5-FU) on viability, cell cycle, and apoptosis status of HCT116 and Caco2 cells. (A) Cell viability of HCT116 cells. (B) Cell viability of Caco-2 cells. (C) Cell cycle of HCT116 cells. (D) Cell cycle of Caco-2 cells. (E) Cell apoptosis in HCT116 cells. (F) Cell apoptosis in Caco-2 cells. Data are presented as the mean of three independent experiments. \* $p < 0.05$ ; \*\* $p < 0.01$ .

## 2.2. Effects of LMWF and 5-FU on cell cycle

In HCT116 cells, the cell cycle distribution did not change significantly after treatment with LMWF (Figure 1C). Moreover, after 5-FU treatment, the proportion of sub-G1 and G0/G1 cells was significantly increased, and the proportion of G2M cells was significantly decreased ( $p < 0.01$ ). However, the proportion of S-phase cells did not change significantly after treatment with 5-FU. After treatment with the combination of LMWF and 5-FU, the proportion of S-phase cells was significantly increased compared with those treated with LMWF or 5-FU ( $p < 0.01$ ). However, in Caco-2 cells (Figure 1D), the cell cycle distribution did not significantly differ after treatment with LMWF, 5-FU, or the combination of LMWF and 5-FU (all  $p > 0.05$ ).


## 2.3. Effects of LMWF and 5-FU on apoptosis

In HCT116 cells, fucoidan did not significantly induce early and late apoptosis, whereas 5-FU significantly induced late apoptosis ( $p < 0.01$ ). Moreover, LMWF significantly enhanced late apoptosis caused by 5-FU ( $p < 0.01$ , Figure 1E). In Caco-2 cells, LMWF and 5-FU induced significantly late apoptosis ( $p < 0.05$ ); however, LMWF did not significantly enhance the effects of 5-FU on late apoptosis induction (Figure 1F).

## 2.4. Signaling pathways responsible for LMWF and 5-FU effects on apoptosis in HCT116 cells

The mutation statuses of HCT 116 colon cancer cells are KRAS mutation (p.G13D) and Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) mutation (p.H1047R) [17]. The Jun-N-terminal kinase (JNK) signaling pathway has been reported to be associated with apoptosis [18–20]. Activated JNK can cause the phosphorylation of mitochondrial proteins (Bcl-2 and Bcl-xl) to then induce apoptosis [19]. The inhibition of JNK has been reported to be associated with resistance to chemotherapeutic drugs in various human cancer cells [19]. Moreover, JNKs are associated with the regulation of both intrinsic and extrinsic apoptosis processes [20]. Therefore, in the present study, we investigated whether the JNK signaling pathway is involved in the apoptosis

caused by the combined administration of LMWF and 5-FU. The expression of phosphorylated JNK (p-JNK) protein was significantly increased in cells at 6 h after treatment with the combination of LMWF and 5-FU relative to cells and cells treated with LMWF or 5-FU (all  $p < 0.05$ ; Figure 2). However, the expression of total JNK protein did not significantly increase relative to cells treated with LMWF or 5-FU. Cleaved poly (ADP-ribose) polymerase (PARP), the substrate of caspase-3, is a key marker of apoptosis [21,22]. The expression of the cleaved PARP protein was significantly increased in cells at 24 h after treatment with the combination of LMWF and 5-FU compared with control cells and those treated with LMWF or 5-FU (all  $p < 0.05$ , Figure 2). However, the expression of the cleaved PARP protein was not significantly increased at 6 h after treatment with the combination of LMWF and 5-FU. Therefore, based on these results, LMWF may enhance the effects of 5-FU on apoptosis of the HCT116 cells through the JNK signaling pathway.




**Figure 2.** Expression of p-JNK protein, JNK protein, PARP, and cleaved PARP in HCT116 cells after treatment with LMWF, 5-FU, and the combination of LMWF and 5-FU. Data are presented as the mean of three independent experiments. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

### 2.5. Effects of signaling pathways responsible for LMWF and 5-FU on decreased viability of Caco-2 cells

Caco-2 cells are KRAS wild-type and PIK3CA wild-type colon cancer cells [17]. The cellular mesenchymal-epithelial transition (c-MET) signaling pathway has been reported to be associated with carcinogenesis, invasion, and metastasis in various cancers, including CRC [23,24]. Compared with the expression in normal colon mucosa, the overexpression of c-Met mRNA and protein is significantly increased in CRC tumors [23]. Moreover, the overexpression of c-MET has been reported to be associated with the metastasis and progression of CRC [23]. Furthermore, the c-MET signaling pathway also cross-talks with other cell membrane receptors, including vascular endothelial growth factor receptor (VEGFR) and EGFR [23]. A study reported that the inhibition of the c-MET signaling pathway is a potential treatment modality for various human cancers, including CRC [24]. Therefore, in the present study, we analyzed whether the c-MET signaling pathway is involved in the suppression of Caco-2 cell viability caused by treatment with the

combination of LMWF and 5-FU. The expression of the c-MET protein was significantly decreased in cells at 6 h after combined treatment with LMWF and 5-FU compared with control cells and those treated with LMWF or 5-FU (all  $p < 0.05$ ; Figure 3A and 3B). Moreover, the expressions of KRAS and p-ERK proteins were significantly decreased in cells at 6 and 24 h, respectively, after treatment with the combination of LMWF and 5-FU compared with control cells and those treated with LMWF or 5-FU ( $p < 0.05$ ; Figure 3A). Similarly, the expressions of PI3K and p-AKT proteins were significantly decreased in cells at 6 and 24 h, respectively, after treatment with the combination of LMWF and 5-FU compared with control cells and those treated with LMWF or 5-FU ( $p < 0.05$ ; Figure 3B). Therefore, based on these findings, LMWF may enhance the suppressive effects of 5-FU on the viability of Caco-2 cells through both c-MET/KRAS/ERK and c-MET/PI3K/AKT signaling pathways.




**Figure 3.** (A) Expressions of c-MET protein, KRAS protein, p-ERK, and ERK in Caco-2 cells after treatment with LMWF, 5-FU, and combination of LMWF and 5-FU. (B) Expressions of c-MET protein, PI3K protein, and p-AKT in Caco-2 cells after treatment with LMWF, 5-FU, and combination of LMWF and 5-FU. Data are presented as the means of three independent experiments. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

## 2.6. Effects of LMWF and 5-FU on migration of colon cancer cells

The migration of colon cancer cells was assessed using a wound healing assay. Cell migration was significantly suppressed after treatment with LMWF or 5-FU in HCT116 and Caco-2 cells (all  $p < 0.05$ ; Figure 4A and 4B). Furthermore, cell migration was further suppressed after treatment with the combination of LMWF and 5-FU in HCT116 and Caco-2 cells (all  $p < 0.05$ ; Figure 4A and 4B). Therefore, LMWF may enhance the suppressive effects of 5-FU on tumor cell migration in HCT116 and Caco-2 cells.






**Figure 4.** Migration of colon cancer cells after treatment with LMWF, 5-FU, and combination of LMWF and 5-FU. (A) HCT116 cells (B) Caco-2 cells. \* $p < 0.05$ .

#### 2.7. Effects of signal pathways responsible for LMWF and 5-FU on suppressive effects of migration in HCT 116 and Caco2 cells

The proteolysis and disruption of ECM are important in the invasion and metastasis of malignant cells. Matrix metalloproteinases (MMPs) are important proteolytic enzymes involved in the proteolysis and disruption of ECM [4,25]. MMP-2 has been reported to be associated with invasion and metastasis in CRC [4,25]. Therefore, in the present study, we explored whether the MMP-2 signaling pathway is involved in the suppression of migration in HCT116 and Caco-2 cells caused by combination treatment with LMWF and 5-FU. The expression of c-MET protein was significantly decreased in cells at 6 h after combination treatment with LMWF and 5-FU compared with control cells and those treated with LMWF or 5-FU in HCT116 cells ( $p < 0.05$ ; Figure 5A) and Caco-2 cells ( $p < 0.05$ ; Figure 5B). Moreover, the expression of MMP-2 protein was significantly decreased in cells at 24 h after combination treatment with LMWF and 5-FU compared with control cells and those treated with LMWF or 5-FU in HCT116 cells ( $p < 0.05$ ; Figure 5A) and Caco-2 cells ( $p < 0.05$ ; Figure 5B). Consequently, according to these results, LMWF may enhance the effects of 5-FU on the suppression of migration in HCT116 and Caco-2 cells through the c-MET/MMP-2 signaling pathway.



**Figure 5.** Protein expressions of c-MET and MMP-2 in colon cancer cells after treatment with LMWF, 5-FU, and combination of LMWF and 5-FU. (A) HCT116 cells. (B) CaCO-2 cells. \* $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

### 3. Discussion

Fucoidan has been reported to exhibit with anticancer activities in various cancer types, including CRC [6–12]. Moreover, fucoidan was reported to enhance the inhibitory effects of co-treatment chemotherapeutic medicines for gastric cancer, esophageal cancer, breast cancer, CRC, and lung cancer [10]. When administered in combination, LMWF has been demonstrated to enhance the effect of chemotherapy and to prevent cachexia-associated muscle atrophy [26]. 5-FU is a critical component of the systemic chemotherapy regimen commonly used for different malignant tumors, including CRC [14]. At present, EGFR monoclonal antibodies (e.g. cetuximab and panitumumab) are used in combination with a fluoropyrimidine-based chemotherapy regimen to treat patients with mCRC [27]. However, EGFR monoclonal antibodies are effective only for patients with wild-type *RAS* gene mCRC. Moreover, considering the results of our previous study [15], we hypothesize that LMWF augments the anti-cancer effect of fluoropyrimidine-based chemotherapy. Therefore, we performed an *in vitro* cell lines study in cell lines to elucidate the role of LMWF in enhancing the anti-cancer effect of fluoropyrimidine-based chemotherapy. The mutation statuses of HCT 116 and CaCO-2 cells are *KRAS* mutation (p.G13D) and *KRAS* wild type, respectively [17]; therefore, both HCT 116 and CaCO-2 cells were used in the present study.

In the present study, the viabilities of both HCT 116 and CaCO-2 cells were significantly reduced by LMWF and 5-FU. Kim *et al.* reported that the growth of HT29 colon cancer cells was significantly inhibited after administration with 500  $\mu\text{g/mL}$  fucoidan for 48 h [28]. Han *et al.* reported that fucoidan suppressed the proliferation of HT29 colon cancer cells [4]. Park *et al.* also demonstrated that the viability of HCT116 colon cancer

cells was gradually reduced by treatment with fucoidan [29], and the growth of Caco-2 colon cancer cells was also inhibited after treatment with fucoidan [30]. Moreover, the viability of both HCT116 and Caco-2 cells was further significantly reduced by the combination therapy of LMWF and 5-FU. Therefore, LMWF may enhance the suppressive effects of 5-FU on the viability of both HCT116 and Caco-2 cells. Fucoidan has been studied as a food supplement or a complementary agent to decrease the toxicity and enhance the efficacy of chemotherapeutic agents [31]. Vishchuk *et al.* demonstrated that fucoidan from the brown alga *Saccharina cichorioides* could enhance the growth inhibitory activity of resveratrol in HCT116 colon cancer cells [32]. Furthermore, fucoidan is considered a complementary agent that can enhance the efficacy of chemotherapeutic agents in various cancer cells, including lung cancer, breast cancer, and esophageal cancer [31].

In the present study, we demonstrated that LMWF enhanced the suppressive effects of 5-FU on viability of HCT116 cells through the induction of cell cycle arrest in the S phase and late apoptosis. Park *et al.* [29] also revealed that fucoidan induced apoptosis and cell cycle arrest in HCT116 cells; however, Park *et al.* [29] reported that fucoidan induced cell cycle arrest in the G1 phase in HCT116 cells. Kim *et al.* [28] reported that fucoidan induced cell cycle arrest in the sub-G1 phase in HT29 cells. In this study, we further investigated the mechanism underlying the LMWF-induced enhancement of the suppressive effects of 5-FU on the apoptosis of HCT116 cells, and we demonstrated the involvement of the JNK signaling pathway in the LMWF-induced enhancement. In leukemia cells, the signaling pathway of ERK1/2 and JNK was reportedly involved in fucoidan-induced apoptosis [33]. HCT116 cell apoptosis caused by fucoidan also could be induced by modulating endoplasmic reticulum stress cascades [34].

In Caco-2 cells, LMWF enhanced the suppressive effects of 5-FU on cell viability, but LMWF did not significantly induce cell cycle arrest. Although LMWF significantly induced late apoptosis, LMWF did not significantly enhance the effects of 5-FU on late apoptosis induction. We demonstrated that LMWF enhanced the suppressive effects of 5-FU on the viability of Caco-2 cells through both c-MET/KRAS/ERK and c-MET/PI3K/AKT signaling pathways. HT 29 and Caco-2 cells are PIK3CA wild-type colon cancer cells [17]. Kim *et al.* [35] reported that fucoidan inhibited the viability of HT-29 cells through the insulin receptor substrate-1 (IRS-1)/PI3K/AKT pathway. Han *et al.* [4] also revealed the suppressive effects of fucoidan on HT 29 cells through the PI3K-Akt-mTOR signaling pathway. Narayani *et al.* [30] demonstrated that fucoidan induced the apoptosis of Caco-2 cells by increasing the production of reactive oxygen species.

The c-MET signaling pathway has been reported to be associated with invasion and metastasis in CRC [23,24]. MMP-2 is an invasion-related protein; thus, we detected the expression of MMP-2 to investigate the effects of LMWF and 5-FU on the migration of tumor cells. In the present study, we demonstrated that LMWF enhanced the suppressive effects of 5-FU on tumor cell migration in HCT116 and Caco-2 cells through the c-MET/MMP-2 signaling pathway. Han *et al.* [4] also reported that fucoidan suppressed migration of HT29 colon cancer cells by reducing the expression of MMP-2. In the mouse hepatocarcinoma cell line Hca-F, the expression of MMP-2 was downregulated by fucoidan [36].

## 4. Materials and Methods

### 4.1. Preparation of LMF

The LMF used in the present study was extracted from *S. hemiphyllum* and was prepared by Hi-Q Marine Biotech International Ltd. (Taipei, Taiwan), with Good Manufacturing Practice certification. LMF powder has also received the Symbol of National Quality certification in Taiwan. LMF was obtained by enzyme hydrolysis of the original fucoidan, and it has an average molecular weight of 0.8 KDa (92.1%). LMF has a fucose content of  $210.9 \pm 3.3$  mmol/g and a sulfate content of  $38.9\% \pm 0.4\%$  (w/w) [14]. LMF powder was dissolved in double-distilled H<sub>2</sub>O and stirred at 65 °C, filter-sterilized through a 0.45-



µm MF-Millipore membrane filter (EMD Millipore, Darmstadt, Germany) and stored at -20 °C. 5-FU was purchased from the Sigma Aldrich (Sigma-Aldrich, St. Louis, MO, USA).

#### 4.2. Cell culture

The human colon cancer cell lines HCT116 and Caco-2 were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). All cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco), penicillin (100 units/mL) and streptomycin (100 µg/mL) (Gibco) in a humid atmosphere containing 5% CO<sub>2</sub> at 37°C.

#### 4.3. Cell viability assay

Cell viability was determined using a 3-(4,5-dimethylthiazol-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Sigma-Aldrich, St. Louis, MO, USA). Cells ( $1 \times 10^4$  cells/well) were seeded into 96-well culture plates and incubated overnight at 37 °C before being treated with LMWF (800 µg/mL), 5-FU (10 µg/mL), and the combination of LMWF and 5-FU. After 24 h, 20 µL of 5 mg/mL MTT was added to each well and incubated at 37 °C for 2 h. The medium was replaced with 100 µL of dimethyl sulfoxide to dissolve the precipitate. Absorbance was measured at a wavelength of 570 nm by a 96-well microplate reader (BioTeK Instruments, Winooski, VT, USA).

#### 4.4. Wound-healing migration assay

Cell migration was assessed using a wound healing assay. Cells were cultured in 12-well plates, and when cells formed a monolayer, a 200-µL pipette tip was used to scratch a wound through the entire center of the well by manual scraping. At 0 and 24 h after the wounding, the migrated cells were counted under a microscope. The images of each wounded area were obtained using a bright field microscope, and wound closure was measured with Image-J software.

#### 4.5. Cell cycle analysis

Cells ( $1 \times 10^6$ ) were treated with LMWF (800 µg/mL), 5-FU (10 µg/mL), and the combination of LMWF and 5-FU for 24 h. Cells were subsequently fixed with 70% ice-cold ethanol at -20 °C for 1 h and resuspended in propidium iodide (PI) (Sigma-Aldrich) in the dark at room temperature for 20 min. Finally, the cell cycle distribution was analyzed using a FACScan cytofluorimeter (Becton Dickinson, Franklin Lakes, NJ, USA) with the CellQuest software (BD Biosciences, San Jose, CA, USA).

#### 4.6. Analysis of cell apoptosis and necrosis

Annexin V-FITC (Thermo Fisher Scientific, Waltham, MA, USA) and PI (Sigma-Aldrich) were applied for apoptosis analysis. Cells ( $1 \times 10^6$ ) were fixed with ice-cold ethanol and were treated with LMWF, 5-FU, and the combination of LMWF and 5-FU for 24 h. Cells were subsequently incubated with Annexin V-FITC and PI in the dark at room temperature. The stained cells were analyzed using the FACScan cytofluorimeter (Becton Dickinson, Franklin Lakes, NJ, USA).

#### 4.7. Western blot analysis

Cells were harvested and lysed with RIPA buffer (Merck Millipore, Burlington, MA, USA), protease inhibitor cocktail (Sigma-Aldrich), and phosphatase inhibitor cocktail (Sigma-Aldrich). Protein samples (25 µg) were resolved on 10% gel SDS-PAGE, and the separated proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Merck Millipore, Burlington, MA, USA). After the membrane was blocked with 5% skim milk for 1 h, it was incubated with primary antibodies, such as anti-Met (Cell Signaling Technology, Danvers, MA, USA), anti-p-JNK (Cell Signaling Technology), anti-JNK (Cell Signaling Technology), anti-PARP (Cell Signaling Technology), anti-MMP2 (Cell Signaling Technology), anti-pAkt (Cell Signaling Technology), anti-pErk (Cell Signaling

Technology), anti-Erk (Cell Signaling Technology), anti-KAS (Abcam plc, Cambridge, England, UK), anti-PI3K (Abcam plc), and anti-GAPDH (Abcam plc) overnight at 4 °C. After being washed three times with phosphate-buffered saline (PBS) containing Tween 20 (PBS-Tween 20), the PVDF membrane was incubated with the secondary antibody at room temperature for 1 h. After the membrane was washed with PBS-Tween 20, immunoreactive proteins were detected using a SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Waltham, MA, USA).

#### 4.8. Statistical analysis

All experimental data are expressed as the mean  $\pm$  standard deviation. Significant differences between the two groups were determined using Student's *t* test. A *p* value less than 0.05 was considered statistically significant.

### 5. Conclusions

We demonstrated that LMWF could enhance the anti-cancer efficacy of 5-FU through its effects on tumor cell viability and migration in both colon cancer cell types of HCT116 (*KRAS*-mutated type) and Caco-2 (*KRAS* wild-type). However, the associated signaling pathways are different. In HCT116 cells, LMWF enhances the suppressive efficacy of 5-FU through the induction of cell cycle arrest and JNK-mediated apoptosis. In Caco-2 cells, LMWF enhances the suppressive efficacy of 5-FU through the c-MET/*KRAS*/ERK and c-MET/PI3K/AKT signaling pathways. In both HCT116 and Caco-2 cells, LMWF enhances the suppressive effects of 5-FU on tumor cell migration through treatment through the c-MET/MMP-2 signaling pathway. LMWF is a potential complementary agent that enhances the efficacy of fluoropyrimidine-based chemotherapy regimen in CRC with wild-type and mutated *KRAS* gene. However, further *in vitro* studies and clinical trials are necessary to validate the results of the present study.

**Author Contributions:** Conceptualization, CWH, YCC, and JYW; methodology, CWH, YCC, TKC, and HLT; formal analysis, CWH, HLT, WCS, and TCY; data curation, CWH, TCY, CJM, PJC, CCL, HLT, and JYW; writing—original draft preparation, CWH; writing—review and editing, YCC, TKC, HLT, and JYW; supervision, JYW. All authors have read and agreed to the published version of the manuscript.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable

**Acknowledgments:** This work was supported by grants through funding from the Ministry of Science and Technology (MOST 109-2314-B-037-035, MOST 109-2314-B-037-040, MOST 109-2314-B-037-046-MY3) and the Ministry of Health and Welfare (MOHW107-TDU-B-212-123006, MOHW107-TDU-B-212-114026B, MOHW108-TDU-B-212-133006, MOHW109-TDU-B-212-134026, MOHW109-TDU-B-212-114006) and funded by the health and welfare surcharge of on tobacco products, and the Kaohsiung Medical University Hospital (KMUH109-9R32, KMUH109-9R33, KMUH109-9R34, KMUH109-9M30, KMUH109-9M31, KMUH109-9M32, KMUH109-9M33, KMUHS10903, KMU-HSA10903, KMUH-DK(C)110010, KMUH-DK(B)110004-3) and KMU Center for Cancer Research (KMU-TC109A04-1) as well as and a KMU Center for Liquid Biopsy and Cohort Research Center Grant (KMU-TC109B05), Kaohsiung Medical University. In addition, this study was supported by the Grant of Taiwan Precision Medicine Initiative, Academia Sinica, Taiwan, R.O.C.

**Conflicts of Interest:** The authors declare no conflict of interest.

### References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* **2018**,68, 394-424.
2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abdulle ASM, Abebe ND, Abraha HN, Abu-Raddad LJ, Abualhasan A, Adedeji IA, Advani SM, Afarideh M, Afshari M, Aghaali M, Agius D, Agrawal S, Ahmadi A, Ahmadian E, Ahmadpour E, Ahmed MB, Akbari ME, Akinyemiju T, Al-Aly Z, AlAbdulKader AM, Alahdab F, Alam T, Alamene GM, Alemnew BTT, Alene KA, Alinia C, Alipour V, Aljunid SM, Bakeshei FA, Almadi MAH, Almasi-Hashiani A, Alsharif U, Alsowaidi S, Alvis-Guzman N, Amini E,

Amini S, Amoako YA, Anbari Z, Anber NH, Andrei CL, Anjomshoa M, Ansari F, Ansariadi A, Appiah SCY, Arab-Zozani M, Arabloo J, Arefi Z, Aremu O, Areri HA, Artaman A, Asayesh H, Asfaw ET, Ashagre AF, Assadi R, Ataenia B, Atalay HT, Ataro Z, Atique S, Ausloos M, Avila-Burgos L, Avokpaho EFGA, Awasthi A, Awoke N, Ayala Quintanilla BP, Ayanore MA, Ayele HT, Babaee E, Bacha U, Badawi A, Bagherzadeh M, Bagli E, Balakrishnan S, Balouchi A, Bärnighausen TW, Battista RJ, Behzadifar M, Behzadifar M, Bekele BB, Belay YB, Belayneh YM, Berfield KKS, Berhane A, Bernabe E, Beuran M, Bhakta N, Bhattacharyya K, Biadgo B, Bijani A, Bin Sayeed MS, Birungi C, Bisignano C, Bitew H, Bjørge T, Bleyer A, Bogale KA, Bojia HA, Borzi AM, Bosetti C, Bou-Orm IR, Brenner H, Brewer JD, Briko AN, Briko NI, Bustamante-Teixeira MT, Butt ZA, Carreras G, Carrero JJ, Carvalho F, Castro C, Castro F, Catalá-López F, Cerin E, Chaiah Y, Chanie WF, Chattu VK, Chaturvedi P, Chauhan NS, Chehraz M, Chiang PP, Chichiabellu TY, Chido-Amajuoyi OG, Chimed-Ochir O, Choi JJ, Christopher DJ, Chu DT, Constantin MM, Costa VM, Crocetti E, Crowe CS, Curado MP, Dahlawi SMA, Damiani G, Darwish AH, Daryani A, das Neves J, Demeke FM, Demis AB, Demissie BW, Demoz GT, Denova-Gutiérrez E, Derakhshani A, Deribe KS, Desai R, Desalegn BB, Desta M, Dey S, Dharmaratne SD, Dhimal M, Diaz D, Dinberu MTT, Djalalinia S, Doku DT, Drake TM, Dubey M, Dubljanin E, Duken EE, Ebrahimi H, Effiong A, Eftekhari A, El Sayed I, Zaki MES, El-Jaafary SI, El-Khatib Z, Elemineh DA, Elkout H, Ellenbogen RG, Elsharkawy A, Emamian MH, Endalew DA, Endries AY, Eshradi B, Fadhil I, Fallah Omrani V, Faramarzi M, Farhangi MA, Farioli A, Farzadfar F, Fentahun N, Fernandes E, Feyissa GT, Filip I, Fischer F, Fisher JL, Force LM, Foroutan M, Freitas M, Fukumoto T, Futran ND, Gallus S, Gankpe FG, Gayesa RT, Gebrehiwot TT, Gebremeskel GG, Gedefaw GA, Gelaw BK, Geta B, Getachew S, Gezae KE, Ghafourifard M, Ghajar A, Ghashghaee A, Gholamian A, Gill PS, Ginindza TTG, Girmay A, Gizaw M, Gomez RS, Gopalani SV, Gorini G, Goulart BNG, Grada A, Ribeiro Guerra M, Guimaraes ALS, Gupta PC, Gupta R, Hadkhale K, Haj-Mirzaian A, Haj-Mirzaian A, Hamadeh RR, Hamidi S, Hanfore LK, Haro JM, Hasankhani M, Hasanzadeh A, Hassen HY, Hay RJ, Hay SI, Henok A, Henry NJ, Herteliu C, Hidru HD, Hoang CL, Hole MK, Hoogar P, Horita N, Hosgood HD, Hosseini M, Hosseinzadeh M, Hostiuc M, Hostiuc S, Househ M, Hussien MM, Ileanu B, Illic MD, Innos K, Irvani SSN, Iseh KR, Islam SMS, Islami F, Jafari Balalami N, Jafarinia M, Jahangiri L, Jahani MA, Jahanmehr N, Jakovljevic M, James SL, Javanbakht M, Jayaraman S, Jee SH, Jenabi E, Jha RP, Jonas JB, Jonnagaddala J, Joo T, Jungari SB, Jürisson M, Kabir A, Kamangar F, Karch A, Karimi N, Karimian A, Kasaeian A, Kasahun GG, Kassa B, Kassa TD, Kassaw MW, Kaul A, Keiyoro PN, Kelbore AG, Kerbo AA, Khader YS, Khalilarjmandi M, Khan EA, Khan G, Khang YH, Khatab K, Khater A, Khayamzadeh M, Khazaei-Pool M, Khazaei S, Khoja AT, Khosravi MH, Khubchandani J, Kianipour N, Kim D, Kim YJ, Kisa A, Kisa S, Kissimova-karbek K, Komaki H, Koyanagi A, Krohn KJ, Bicer BK, Kugbey N, Kumar V, Kuupiel D, La Vecchia C, Lad DP, Lake EA, Lakew AM, Lal DK, Lami FH, Lan Q, Lasrado S, Lauriola P, Lazarus JV, Leigh J, Leshargie CT, Liao Y, Limenih MA, Listl S, Lopez AD, Lopukhov PD, Lunevicius R, Madadin M, Magdeldin S, El Razek HMA, Majeed A, Maleki A, Malekzadeh R, Manafi A, Manafi N, Manamo WA, Mansourian M, Mansournia MA, Mantovani LG, Maroufizadeh S, Martini SMS, Mashamba-Thompson TP, Massenburg BB, Maswabi MT, Mathur MR, McAlinden C, McKee M, Meheretu HAA, Mehrotra R, Mehta V, Meier T, Melaku YA, Meles GG, Meles HG, Melese A, Melku M, Memiah PTN, Mendoza W, Menezes RG, Merat S, Meretoja TJ, Mestrovic T, Miazgowski B, Miazgowski T, Mihretie KMM, Miller TR, Mills EJ, Mir SM, Mirzaei H, Mirzaei HR, Mishra R, Moazen B, Mohammad DK, Mohammad KA, Mohammad Y, Darwesh AM, Mohammadbeigi A, Mohammadi H, Mohammadi M, Mohammadian M, Mohammadian-Hafshejani A, Mohammadoo-Khorasani M, Mohammadpourhodki R, Mohammed AS, Mohammed JA, Mohammed S, Mohebi F, Mokdad AH, Monasta L, Moodley Y, Moosazadeh M, Moossavi M, Moradi G, Moradi-Joo M, Moradi-Lakeh M, Moradpour F, Morawska L, Morgado-da-Costa J, Morisaki N, Morrison SD, Mosapour A, Mousavi SM, Muche AA, Muhammed OSS, Musa J, Nabhan AF, Naderi M, Nagarajan AJ, Nagel G, Nahvijou A, Naik G, Najafi F, Naldi L, Nam HS, Nasiri N, Nazari J, Negoi I, Neupane S, Newcomb PA, Nggada HA, Ngunjiri JW, Nguyen CT, Nikniaz L, Ningrum DNA, Nirayo YL, Nixon MR, Nnaji CA, Nojomi M, Nosratnejad S, Shiadeh MN, Obsa MS, Ofori-Asenso R, Ogbo FA, Oh IH, Olagunju AT, Olagunju TO, Oluwasanu MM, Omonisi AE, Onwujekwe OE, Oommen AM, Oren E, Ortega-Altamirano DDV, Ota E, Otstavnov SS, Owolabi MO, P A M, Padubidri JR, Pakhale S, Pakpour AH, Pana A, Park EK, Parsian H, Pashaei T, Patel S, Patil ST, Pennini A, Pereira DM, Piccinelli C, Pillay JD, Pirestani M, Pishgar F, Postma MJ, Pourjafar H, Pourmalek F, Pourshams A, Prakash S, Prasad N, Qorbani M, Rabiee M, Rabiee N, Radfar A, Rafiei A, Rahim F, Rahimi M, Rahman MA, Rajati F, Rana SM, Raoofi S, Rath GK, Rawaf DL, Rawaf S, Reiner RC, Renzaho AMN, Rezaei N, Rezapour A, Ribeiro AI, Ribeiro D, Ronfani L, Roro EM, Roshandel G, Rostami A, Saad RS, Sabbagh P, Sabour S, Saddik B, Safiri S, Sahebkar A, Salahshoor MR, Salehi F, Salem H, Salem MR, Salimzadeh H, Salomon JA, Samy AM, Sanabria J, Santric Milicevic MM, Sartorius B, Sarveazad A, Sathian B, Satpathy M, Savic M, Sawhney M, Sayyah M, Schneider IJC, Schöttker B, Sekerija M, Sepanlou SG, Sepehrimanesh M, Seyedmousavi S, Shaahmadi F, Shabaninejad H, Shahbaz M, Shaikh MA, Shamshirian A, Shamsizadeh M, Sharafi H, Sharafi Z, Sharif M, Sharifi A, Sharifi H, Sharma R, Sheikh A, Shirkoobi R, Shukla SR, Si S, Siabani S, Silva DAS, Silveira DGA, Singh A, Singh JA, Sisay S, Sitas F, Sobngwi E, Soofi M, Soriano JB, Stathopoulou V, Sufiyan MB, Tabarés-Seisdedos R, Tabuchi T, Takahashi K, Tamtaji OR, Tarawneh MR, Tassew SG, Taymoori P, Tehrani-Banihashemi A, Temsah MH, Temsah O, Tesfay BE, Tesfay FH, Teshale MY, Tessema GA, Thapa S, Tlaye KG, Topor-Madry R, Tovani-Palone MR, Traini E, Tran BX, Tran KB, Tsadik AG, Ullah I, Uthman OA, Vacante M, Vaezi M, Varona Pérez P, Veisani Y, Vidale S, Violante FS, Vlassov V, Vollset SE, Vos T, Vosoughi K, Vu GT, Vujcic IS, Wabinga H, Wachamo TM, Wagnev FS, Waheed Y, Weldegebreal F, Weldesamuel GT, Wijeratne T, Wondafrash DZ, Wonde TE, Wondmieni AB, Workie HM, Yadav R, Yadegar A, Yadollahpour A, Yaseri M, Yazdi-Feyzabadi V, Yeshaneh A, Yimam MA, Yimer EM, Yisma E, Yonemoto N, Younis MZ, Yousefi B, Yousefifard M, Yu C, Zabeh E, Zadnik V, Moghadam TZ, Zaidi Z, Zamani M, Zandian H, Zangeneh A, Zaki L, Zendehele K, Zenebe ZM, Zewale TA, Ziapour A, Zodepy S, Murray CJL. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. **JAMA** 2019, 5, 1749–1768.

3. Ministry of Health and Welfare, the Executive Yuan, Republic of China. Health and Vital Statistics. <http://www.mohw.gov.tw/CHT/DOS/Statistic.aspx>
4. Han YS, Lee JH, Lee SH. Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways. *Mol Med Rep* **2015**, 12, 3446-3452.
5. Palanisamy S, Vinosha M, Marudhupandi T, Rajasekar P, Prabhu NM. Isolation of fucoidan from *Sargassum polycystum* brown algae: Structural characterization, in vitro antioxidant and anticancer activity. *Int J Biol Macromol* **2017**, 102,405-412.
6. van Weelden G, Bobiński M, Okla K, van Weelden WJ, Romano A, Pijnenborg JMA. Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms. *Mar Drugs* **2019**, 17, 32.
7. Lin Y, Qi X, Liu H, Xue K, Xu S, Tian Z. The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations. *Cancer Cell Int* **2020**, 20, 154.
8. Wang L, Wang X, Wu H, Liu R. Overview on biological activities and molecular characteristics of sulfated polysaccharides from marine green algae in recent years. *Mar Drugs* **2014**, 12, 4984-5020.
9. Senthilkumar K, Manivasagan P, Venkatesan J, Kim SK. Brown seaweed fucoidan: biological activity and apoptosis, growth signaling mechanism in cancer. *Int J Biol Macromol* **2013**, 60, 366-374.
10. Wu L, Sun J, Su X, Yu Q, Yu Q, Zhang P. A review about the development of fucoidan in antitumor activity: Progress and challenges. *Carbohydr Polym* **2016**, 154, 96-111.
11. Mabate B, Daub CD, Malgas S, Edkins AL, Pletschke BI. Fucoidan Structure and Its Impact on Glucose Metabolism: Implications for Diabetes and Cancer Therapy. *Mar Drugs*. **2021**, 19, 30.
12. Sanjeewa KKA, Lee JS, Kim WS, Jeon YJ. The potential of brown-algae polysaccharides for the development of anticancer agents: An update on anticancer effects reported for fucoidan and laminaran. *Carbohydr Polym* **2017**, 177, 451-459.
13. Cheng HC, Chang TK, Su WC, Tsai HL, Wang JY. Narrative review of the influence of diabetes mellitus and hyperglycemia on colorectal cancer risk and oncological outcomes. *Transl Oncol* **2021**, 14, 101089.
14. Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. *Pharmacol Ther* **2020**, 206, 107447.
15. Tsai HL, Tai CJ, Huang CW, Chang FR, Wang JY. Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial. *Mar Drugs* **2017**, 15, 122.
16. Huang CW, Ma CJ, Su WC, Chen YT, Tsai HL, Yeh YS, Chang TK, Hsu WH, Yu FJ, Wang JY. Prognostic Value of EGFR Expression for Patients with Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy. *Oncol Res* **2020**, Aug 28. two: 10.3727/096504020X15986099915822..
17. Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA. Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. *Mol Cancer* **2017**, 16, 116.
18. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. *Oncogene* **2008**, 27, 6245-6251.
19. Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, He C, Pan H. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. *Cancer Lett*, **2014**, 344, 174-179.
20. Dhanasekaran DN, Reddy EP. JNK-signaling: A multiplexing hub in programmed cell death. *Genes Cancer* **2017**, 8, 682-694.
21. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. *Cancer Biol Ther* **2005**, 4, 139-163.
22. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol* **2007**, 35, 495-516.
23. Safaie Qamsari E, Safaei Ghaderi S, Zarei B, Dorostkar R, Bagheri S, Jadidi-Niaragh F, Somi MH, Yousefi M. The c-Met receptor: Implication for targeted therapies in colorectal cancer. *Tumour Biol* **2017**, 39,1010428317699118.
24. Zhang H, Feng Q, Chen WD, Wang YD. HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers. *Int J Mol Sci* **2018**, 19, 3295.
25. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. *Clin Exp Metastasis* **2009**, 26, 19-34.
26. Chen MC, Hsu WL, Hwang PA, Chen YL, Chou TC. Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice. *Oncotarget* **2016**, 7, 51608-51618.
27. Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. *ESMO Open* **2016**, 1, e000088.
28. Kim IH, Kwon MJ, Nam TJ. Differences in cell death and cell cycle following fucoidan treatment in high-density HT-29 colon cancer cells. *Mol Med Rep* **2017**, 15, 4116-4122.
29. Park HY, Park SH, Jeong JW, Yoon D, Han MH, Lee DS, Choi G, Yim MJ, Lee JM, Kim DH, Kim GY, Choi IW, Kim S, Kim HS, Cha HJ, Choi YH. Induction of p53-Independent Apoptosis and G1 Cell Cycle Arrest by Fucoidan in HCT116 Human Colorectal Carcinoma Cells. *Mar Drugs* **2017**, 15, 154.
30. Narayani SS, Saravanan S, Ravindran J, Ramasamy MS, Chitra J. In vitro anticancer activity of fucoidan extracted from *Sargassum cinereum* against Caco-2 cells. *Int J Biol Macromol* **2019**, 138, 618-628.
31. Hsu HY, Hwang PA. Clinical applications of fucoidan in translational medicine for adjuvant cancer therapy. *Clin Transl Med* **2019**, 8, 15.
32. Vishchuk OS, Ermakova SP, Zvyagintseva TN. The effect of sulfated (1→3)- $\alpha$ -l-fucan from the brown alga *Saccharina cichorioides* Miyabe on resveratrol-induced apoptosis in colon carcinoma Cells.. *Mar Drugs* **2013**, 11, 194-212.
33. Jin JO, Song MG, Kim YN, Park JI, Kwak JY. The mechanism of fucoidan-induced apoptosis in leukemic cells: involvement of ERK1/2, JNK, glutathione, and nitric oxide. *Mol Carcinog* **2010**, 49, 771-782.

- 
34. Chen S, Zhao Y, Zhang Y, Zhang D. Fucoidan induces cancer cell apoptosis by modulating the endoplasmic reticulum stress cascades. *PLoS One* **2014**, 9, e108157.
  35. Kim IH, Nam TJ. Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. *Oncol Rep* **2018**, 39, 1516-1522.
  36. Teng H, Yang Y, Wei H, Liu Z, Liu Z, Ma Y, Gao Z, Hou L, Zou X. Fucoidan Suppresses Hypoxia-Induced Lymphangiogenesis and Lymphatic Metastasis in Mouse Hepatocarcinoma. *Mar Drugs* **2015**, 13, 3514-3530.